Therapeutic innovations in breast cancer

Fanny Le Du; Christophe Perrin; Angélique Brunot; Laurence Crouzet; Thibault De La Motte Rouge; Claudia Lefeuvre-Plesse; Véronique Dieras

doi:10.1016/j.lpm.2019.04.005

Therapeutic innovations in breast cancer

Presse Med. 2019 Oct;48(10):1131-1137. doi: 10.1016/j.lpm.2019.04.005. Epub 2019 May 29.

Authors

Fanny Le Du¹, Christophe Perrin¹, Angélique Brunot¹, Laurence Crouzet¹, Thibault De La Motte Rouge¹, Claudia Lefeuvre-Plesse¹, Véronique Dieras²

Affiliations

¹ Centre Eugène-Marquis, avenue Bataille Flandres-Dunkerque, 35000 Rennes, France.
² Centre Eugène-Marquis, avenue Bataille Flandres-Dunkerque, 35000 Rennes, France. Electronic address: v.dieras@rennes.unicancer.fr.

PMID: 31151842
DOI: 10.1016/j.lpm.2019.04.005

Abstract

Managing endocrine resistance and resistance to endocrine therapy for ER+ HER2- breast cancer with the CDK 4/6 inhibitors in the metastatic setting. New antibodies drug conjugates for HER2+ and TNBC. Targeting DNA damage and synthetic lethality strategies with PARP inhibitors for breast cancer patients harboring BRCA mutation. Immunotherapies in 1st line metastatic setting of TNBC.

Publication types

Review

MeSH terms

Breast Neoplasms / chemistry
Breast Neoplasms / therapy*
Cyclin-Dependent Kinase 4 / antagonists & inhibitors
Cyclin-Dependent Kinase 6 / antagonists & inhibitors
Female
Humans
Immunoconjugates / therapeutic use
Immunotherapy / methods
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
Protein Kinase Inhibitors / therapeutic use
Randomized Controlled Trials as Topic

Substances

Immunoconjugates
Poly(ADP-ribose) Polymerase Inhibitors
Protein Kinase Inhibitors
CDK4 protein, human
CDK6 protein, human
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6